Entero Therapeutics, Inc. (Nasdaq: ENTO) (“Entero” or the “Company”), announces that it has entered into a binding term sheet for a reverse merger transaction (the “Proposed Merger”) with Journey Therapeutics, Inc. (“Journey”), a privately-held, clinical-stage biopharmaceutical company with a next-generation proprietary modular antibody-drug conjugate (ADC)-like, nano-immunoconjugates (NIC) platform. Upon completion of the Proposed Merger, the shareholders of Journey will acquire 99% of the equity of Entero. The combined company is expected to operate under the name Journey Therapeutics, Inc., and will apply for continued trading on The Nasdaq Capital Market.
Read the full article: Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics //
Source: https://www.globenewswire.com/news-release/2024/11/13/2980077/0/en/Entero-Therapeutics-Announces-Proposed-Reverse-Merger-with-Journey-Therapeutics-A-Clinical-Stage-First-in-Class-Next-Generation-ADC-rivalling-Nano-immunoconjugates-Biopharmaceutica.html